LTI Strengthens Strategic Collaboration with Microsoft
Larsen & Toubro Infotech (BSE: 540005, NSE: LTI), a global technology consulting and digital solutions company, has announced the expansion of its collaboration with Microsoft to focus on developing high-value cloud solutions for enterprises. As a part of this multi-year collaboration, LTI has launched a dedicated Microsoft business unit that develops and offers end-to-end digital transformation solutions.
Through this association, LTI will also train 12,000 professionals from its existing workforce on various Microsoft technologies by 2024. The main objective of this effort is to enable skill development of LTI employees that are a part of the Microsoft unit and enhance their competencies across technologies like cloud, data, IoT and security.
Nachiket Deshpande, Chief Operating Officer, LTI, said, “LTI has a long-standing relationship with Microsoft as a strategic partner, service provider, and customer. Our reaffirmed partnership with Microsoft will enable us to innovate and offer 170+ distinct services to our joint customers. Additionally, we will also focus on the training and upskilling of our talent pool that is a part of the dedicated Microsoft business unit, to empower them to meet changing business and market requirements.”
Siddharth Bohra, Chief Business Officer & Head of Cloud Business Unit, LTI, said, “Enterprises across the globe are increasingly embracing cloud, and LTI has made impressive strides in developing a multi-dimensional capability on Azure to meet this demand. As part of this collaboration, LTI and Microsoft will jointly innovate, develop, and sell solutions to assist enterprises in acceleration of their digital transformation journeys.”
Julie Sanford, Vice President, Partner GTM, Programs & Experiences, Microsoft, said, “Through their new Microsoft Business Unit, LTI will be able to help customers implement cloud strategies and drive business transformation across industries and geographies. We look forward to working with LTI as they build new capabilities and deliver innovative solutions on the Microsoft Cloud.”
Through this association, LTI will attain the Solution Partner designation across all the Microsoft Solution Areas. LTI also has the following advanced specializations on Azure:
- SAP on Azure: Validating the capability of implementing SAP solutions on Azure.
- Analytics on Azure: Demonstrating the expertise in delivering analytics solutions in Microsoft Azure.
- Windows Server and SQL Server: Expertise in migrating production workloads to Microsoft Azure.
- Modernization of Web Applications: Validating expertise in migrating and deploying production web application workloads, applying DevOps, and managing app services in Microsoft Azure.
- Kubernetes on Azure: validating capabilities in deploying and managing production workloads in the cloud using containers and managing hosted Kubernetes environments in Azure.
- Low Code Application Development: Expertise in building solutions using Power Apps.
- The Data Warehouse Migration to Microsoft Azure: Validating expertise in analyzing existing workloads and performing ETL operations to migrate data to cloud-based data warehouses.
- Cloud Security:Validates a means for your company to showcase capabilities to implement comprehensive security solutions across Azure, hybrid, and multi-cloud environments.
- Threat Protection: provides a means for your company to showcase proven, verifiable expertise in deploying Microsoft Threat Protection or Microsoft Cloud App Security workloads.
- AI and Machine Learning in Microsoft Azure:Validates capabilities on enabling customer adoption of Al and implementing Azure solutions for Al-powered apps.
LTI is an Azure Expert MSP Partner which demonstrates deep knowledge, extensive experience, and proven success in implementing specialized workloads such as Migration and Modernization, SAP on Azure, Data Analytics, Internet of things (IoT), Security, and Microsoft Dynamics 365.
LTI (NSE: LTI) is a global technology consulting and digital solutions Company helping more than 495 clients succeed in a converging world. With operations in 33 countries, we go the extra mile for our clients and accelerate their digital transformation journeys. Founded in 1997 as a subsidiary of Larsen & Toubro Limited, our unique heritage gives us unrivalled real-world expertise to solve the most complex challenges of enterprises across all industries. Each day, our team of more than 46,000 LTItes enable our clients to improve the effectiveness of their business and technology operations and deliver value to their customers, employees, and shareholders. Find more at https://www.lntinfotech.com or follow us at @LTI_Global.
Connect with LTI:
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Lead- Media Relations
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kapruvia ® approved in Switzerland with additional regulatory decisions expected in H2 202219.8.2022 07:00:00 CEST | Press release
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that they have received approval for Kapruvia® from the Swiss Agency for Therapeutic Products (Swissmedic). Kapruvia® will be the first therapy available for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult hemodialysis patients. Swissmedic approval for Kapruvia® follows approvals by the U.S. Food and Drug Administration, by the European Medicines Agency, by the UK Medicines and Healthcare products Regulatory Agency, as well as by Health Canada. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220818005552/en/ “The approval of Kapruvia® in Switzerland is the next step on our journey to bring this breakthrough treatment to hemodialysis patients living with CKD-associated pruritus around the world,” said Dr. Klaus Henning Jensen, Chief Medical Officer of CSL Vifor. “There is a
European Commission Approves Celltrion Healthcare’s Vegzelma™ (CT-P16, biosimilar bevacizumab) for the Treatment of Multiple Types of Cancer19.8.2022 04:47:00 CEST | Press release
Celltrion Healthcare announced today that the European Commission (EC) has approved Vegzelma™ (CT-P16), a biosimilar bevacizumab referencing EU-approved Avastin®, for the treatment of metastatic breast cancer, non-small cell lung cancer, advanced and/or metastatic renal cell cancer, metastatic carcinoma of the colon or rectum, ovarian cancer and cervical cancer. “The European Commission’s approval of Vegzelma™ will increase access to treatment for patients living with certain types of cancer at an affordable price,” said Kevin Byoung Seo Choi, Senior Vice President and Head of Marketing Division at Celltrion Healthcare. “With proven similarities in efficacy and safety compared to the reference product Avastin®, Vegzelma™ will be available to treat some of the most commonly diagnosed cancers, which collectively affect hundreds of thousands of European patients each year.” The EC approval of Vegzelma™ follows the recommendation for marketing authorisation issued by the Committee for Medi
Dermaliq Therapeutics announces first patient dosed in Phase 1b/2 trial evaluating DLQ02 for treatment of plaque psoriasis18.8.2022 18:27:00 CEST | Press release
Dermaliq Therapeutics, Inc. (Dermaliq), a private, clinical stage pharmaceutical company with a focus on dermatology, today announced first patient dosed in a Phase 1b/2a trial with DLQ02, a topical calcineurin inhibitor. The trial is designed to evaluate the safety, systemic absorption, pharmacodynamics, and clinical efficacy of DLQ02 in patients with plaque psoriasis. “DLQ02 evaluates for the first time hyliQTM, a novel platform technology in dermatology to create best in-class topical therapies with superior bioavailability,” said Betsy Hughes-Formella, PhD, Chief Scientific Officer at Dermaliq. “Calcineurin inhibitors for the treatment of psoriasis are a standard of care when given orally, albeit being associated with significant risk for systemic side effects. DLQ02 is designed to overcome the challenges of topical delivery of this drug class with reduced risk profiles. We are convinced DLQ02 has the potential to transform topical psoriasis therapy for millions of patients.” The r
Aero Secures $65M in Series B Financing to Accelerate the Future of Premium Air Travel18.8.2022 18:00:00 CEST | Press release
Aero Technologies, Inc. the next-generation premium air travel company, which serves routes in both the US and Europe, today announced a $65M capital raise, $50M in Series B funding and $15M in convertible notes, for a total post-money valuation of $300M. The funding round was co-led by AlbaCore Capital Group, one of Europe’s leading alternative investment firms, and returning investors Expa and Keyframe Capital, with new investment from Capital One Ventures. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220818005095/en/ (Photo: Business Wire) Inspired by the golden age of aviation and designed for modern life, Aero is redefining semi-private air travel. Aero serves premium leisure travelers through private terminals, enriching the experience with personalized Concierge services - from booking to touchdown. With its fleet of sleek, black planes, Aero offers elevated, effortless guest experiences to curated destinations with
Veristat is Recognized on the 2022 Inc. 5000 List of America’s Fastest-Growing Private Companies18.8.2022 15:49:00 CEST | Press release
Veristat, global experts in clinical development, registration and post-marketing solutions proudly announces its recognition once again by Inc. Magazine as one of the 5000 fastest-growing private companies in the United States. Since its first appearance on the list in 2015, Veristat has significantly expanded in size, geographic reach and service offering to swiftly guide novel therapies through their clinical development process to regulatory approval and commercialization. Veristat’s team of scientific experts works collaboratively with clients in the biotech and pharmaceutical industries to overcome the many challenges associated with bringing to market products that address current medical shortcomings and maintain their good standing. “Being recognized as one of America’s Fastest-Growing Private Companies is a testament to Veristat’s ability to deliver innovative solutions, bold thinking and versatile engagement models to our clients,” stated Patrick Flanagan, Chief Executive Of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom